Structural Biology Services
Premium Structural Biology Services
X-ray Crystallography, NMR Spectroscopy & Fragment-Based Lead Discovery
SARomics Biostructures is a CRO that provides a wide range of premium structural biology and drug discovery outsourcing services to the biotech industry and academic institutions. We have many years of experience and proven excellence in protein crystallization, X-ray crystallography, BioNMR spectroscopy, biophysical characterization of proteins, fragment screening, and fragment-based drug discovery.
Please visit "about the company" for additional information or contact us directly for a company presentation and discussion of your project.
Please visit "about the company" for additional information or contact us directly for a company presentation and discussion of your project.
To view our services packages, please follow the links below.
Our X-ray crystallography services provide protein crystallization and X-ray structure determination, FastLane™ Premium and FastLane™ standard libraries of verified drug targets (off-the-shelf structures), custom gene-to-structure and protein-ligand complex X-ray structure determination & structure-based lead discovery.
We provide a broad range of custom NMR (BioNMR) spectroscopy services that include peptide, protein, protein-ligand & protein-protein complex NMR assignment and 3D structure determination, NMR fragment screening using 1D or 2D NMR, epitope mapping and dissociation constant (Kd) determinations for compounds.
Antibody and antibody-antigen complex crystallization and high resolution X-ray structure determination, BioNMR and crystallographic characterization of higher order structure (HOS) of biosimilars, comparison with originator antibody and formulation optimization, biophysical characterization of antibodies and biosimilars in solution.
Integrated lead discovery and structure-based drug design (SBDD) include fragment screening, hit identification, hit-to-lead and lead optimization services, proprietary fragment library, and weak-affinity chromatography screening.
High throughput (2000-3000 cmpds/week), robust and accurate (validated against NMR and X-ray) fragment screening using weak-affinity chromatography (WAC™), which also includes binding assay and measurement of fragment affinity to immobilized protein - all in one experiment!
Protein optimization and structure-based design of biological drugs (biologics) and peptides using quantitative structure-activity relationships (QSAR) methodology as implemented in our proprietary ProPHECY™ protein optimization software package.
State-of-the-art Structural Biology Services Platform
Our structural biology services platform is equipped with state-of-the-art instrumentation for protein production, robotic nanoliter-scale crystallization screening, robotic optimization of conditions for crystal growth, and crystallization drop imaging. For X-ray data collection, we use the MAX IV synchrotron radiation facility (image above), located a couple of kilometers from our labs in Lund. Alternatively, we send the crystals to other European synchrotrons. We collect X-ray data approximately every second week.
For NMR spectroscopy services, we have access to high-quality, cutting-edge instrumentation. We provide de novo NMR protein structure determination, protein-ligand/protein-protein complex NMR structure determination, small molecule fragment library screening, and much more…
You may also visit our learning center for an overview of the experimental technologies we use in protein crystallization and X-ray crystallography, NMR spectroscopy, and drug discovery & design services. Our recent blog posts also discuss various aspects and the impact of structural biology in drug discovery.
You may use the form below to contact us if you have any questions related to our technology platform.
For NMR spectroscopy services, we have access to high-quality, cutting-edge instrumentation. We provide de novo NMR protein structure determination, protein-ligand/protein-protein complex NMR structure determination, small molecule fragment library screening, and much more…
You may also visit our learning center for an overview of the experimental technologies we use in protein crystallization and X-ray crystallography, NMR spectroscopy, and drug discovery & design services. Our recent blog posts also discuss various aspects and the impact of structural biology in drug discovery.
You may use the form below to contact us if you have any questions related to our technology platform.
Latest news and blog posts
Aqilion's research alliance with Merck worth €950 million
First-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program made possible by close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
Read more…
Read more…
Library screening: lead-like or fragment libraries?
In this blog post on structural biology and structure-based drug design, we discuss compound screening, a stage central to all drug design strategies discussed earlier. The quality of the compounds we identify in this process will be crucial for the discovery project.
Read more…
Read more…
The dusquetide saga – a structural blast from the past!
A paper describing the interaction of the therapeutic peptide dusquetide with the ZZ domain of the autophagic receptor p62 is featured in Structure. A publication comes around 12 years after the structure solution; it is a pleasant surprise!
Read more…
Read more…